Morbidity in patients with hidradenitis suppurativa
Article first published online: 22 AUG 2002
British Journal of Dermatology
Volume 144, Issue 4, pages 809–813, April 2001
How to Cite
Von Der Werth, J.M. and Jemec, G.B.E. (2001), Morbidity in patients with hidradenitis suppurativa. British Journal of Dermatology, 144: 809–813. doi: 10.1046/j.1365-2133.2001.04137.x
- Issue published online: 22 AUG 2002
- Article first published online: 22 AUG 2002
- Accepted for publication 24 October 2000
- Dermatology Life Quality Index;
- disease quantification;
- hidradenitis suppurativa;
- life quality;
Background Although skin diseases are often immediately visible to both patients and society, the morbidity they cause is only poorly defined. It has been suggested that quality-of-life measures may be a relevant surrogate measure of skin disease. Hidradenitis suppurativa (HS) leads to painful eruptions and malodorous discharge and is assumed to cause a significant degree of morbidity. The resulting impairment of life quality has not previously been quantitatively assessed, although such an assessment may form a pertinent measure of disease severity in HS.
Objectives To measure the impairment of life quality in patients with HS.
Methods In total, 160 patients suffering from HS were approached. The following data were gathered: quality-of-life data (Dermatology Life Quality Index, DLQI questionnaire), basic demographic data, age at onset of the condition and the average number of painful lesions per month.
Results One hundred and fourteen patients participated in the study. The mean ± SD age of the patients was 40·9 ± 11·7 years, the mean ± SD age at onset 21·8 ± 9·9 years and the mean ± SD duration of the disease 18·8 ± 11·4 years. Patients had a mean ± SD DLQI score of 8·9 ± 8·3 points. The highest mean score out of the 10 DLQI questions was recorded for question 1, which measures the level of pain, soreness, stinging or itching (mean 1·55 points, median 2 points). Patients experienced a mean of 5·1 lesions per month.
Conclusions HS causes a high degree of morbidity, with the highest scores obtained for the level of pain caused by the disease. The mean DLQI score for HS was higher than for previously studied skin diseases, and correlated with disease intensity as expressed by lesions per month. This suggests that the DLQI may be a relevant outcome measure in future therapeutic trials in HS.